Alto Neuroscience, Inc. (ANRO) is a clinical-stage biopharmaceutical company based in Mountain View, California, that uses a precision psychiatry platform built on brain biomarkers to develop treatments for depression, bipolar disorder, treatment-resistant depression, and schizophrenia. Its pipeline includes ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208.
On Nov. 18, the stock traded at $26.77, up $1.86, or 7.47%, from the prior session's close of $24.91. The move is definitively to the upside and unfolded with no accompanying corporate announcement or analyst revision. With the broad market slightly lower and biotech benchmarks roughly flat, the gain reflects internal trading dynamics rather than a fundamental development.
No verified news or fundamental catalyst found to explain the session's advance. There was no press release, no 8-K, no clinical data disclosure, and no published rating or price-target change tied to Nov. 18. The most recent company news remains the third-quarter report published Nov. 10, along with routine items such as investor-conference participation and employee inducement grants.
The most consistent technical read is a snap-back after a sharp two-session selloff. Shares fell 8.19% on Nov. 16 and another 8.15% on Nov. 17, pushing the stock down 20% from the Nov. 12 close. The Nov. 17 low of $24.79 landed essentially on the 200-day moving average near $24.80, a level that has repeatedly attracted buyers over the past three months. That confluence of a round-number moving average, an oversold short-term condition, and a 14% short interest in a thin float is a pattern consistent with short covering and dip-buying rather than new information.
The pullback that preceded today's bounce looks like profit-taking. Between the Nov. 5 close of $21.87 and the Nov. 12 close of $31.15, the stock climbed 42.4% in six sessions on above-average volume, including a 15% single-day jump on Nov. 6 and an 8.9% gain on Nov. 11. Even after the two-day retreat, shares remain well above their 52-week low of $12.51 and are up more than 80% over the past year. Today's move recovers only about a third of that giveback, which is typical of a rebound within a corrective phase rather than the start of a new leg higher.
Volume was not the story. Roughly 347,000 shares had changed hands by early afternoon, a pace broadly in line with the 20-day average near 598,000 and below the 10-day average of about 723,000. A 7.5% move on unremarkable turnover points to thin liquidity and a modest order imbalance rather than institutional accumulation.
The move also diverged from the tape. The XBI biotech ETF was up about 0.2% intraday, while the IBB large-cap biotech benchmark slipped 0.3% and the SPY S&P 500 proxy declined 0.4%. Both indices had fallen sharply on Nov. 16 alongside a broader risk-off session, which explains part of the stock's earlier weakness but not the outsized bounce.
Technically, the stock reclaimed its 50-day moving average near $26.20 after briefly breaking below it and used the 200-day average as a floor. Intraday resistance near $27.11 and the Nov. 16 high around $29.54 remain the levels to clear.
The score runs from 0 to 100, where 0 represents no meaningful news and a move that is normal for the stock, and 100 represents transformative news paired with an extreme, rare price move. This event scores 10 out of 100.
The news component is negligible: no verified company-specific catalyst surfaced for the session, and the Q3 update that anchors the fundamental narrative was published a week earlier. The price component is also muted. Today's 7.47% gain is about 2.3 times the stock's average absolute daily move of roughly 3.2% over the last 60 sessions, but moves of that size or larger have occurred seven times in that stretch, including declines of 10.7% and 8.5% and gains of 15.0% and 10.5%. On in-line volume, the two factors combine to a low score.
Attention shifts to the company's 2027 catalyst calendar. Topline Phase 2b data for ALTO-300 in major depressive disorder is expected in the first half of 2027, followed by ALTO-100 in bipolar depression around mid-2027 and the PACE-1 Phase 2b study of ALTO-207 in treatment-resistant depression in the second half of 2027. Management has said a Phase 3 program for ALTO-207 could begin in early 2027 pending FDA alignment.
Financial flexibility is a support: $319.8 million in cash and equivalents is expected to fund operations through 2030, following a $100 million registered direct offering in July 2026 that expanded the share count by nearly 50% year over year. Analyst consensus sits at Strong Buy with an average 12-month target near $38.67, the highest at $60. Risks include further dilution, trial delays, binary clinical outcomes, insider selling earlier in the year, and sensitivity to financing conditions for unprofitable biotech names.
Tickeron operates hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions appear in the curated Trending AI Robots section. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so results vary widely across market regimes. Reviewing the ranked list is a practical way to see which models are adapting best to present volatility. Explore the page to compare current leaders before deciding what fits your approach.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
ANRO saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator turned positive. In 42 of the 47 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
The Moving Average Convergence Divergence (MACD) for ANRO just turned positive on October 20, 2026. Looking at past instances where ANRO's MACD turned positive, the stock continued to rise in 14 of 17 cases over the following month. The odds of a continued upward trend are 82%.
ANRO moved above its 50-day moving average on November 18, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ANRO crossed bullishly above the 50-day moving average on November 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.
Following a +12.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANRO advanced for three days, in 151 of 172 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
The Aroon Indicator entered an Uptrend today. In 118 of 136 cases where ANRO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
The 10-day RSI Indicator for ANRO moved out of overbought territory on November 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 18 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 24 of 30 cases where ANRO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
ANRO broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.503) is normal, around the industry mean (3.592). P/E Ratio (-10.845) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. ANRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology